高龋菌株产生的变链素对口腔链球菌抑制活性的比较

目的 通过比较高龋和无龋儿童变形链球菌临床分离株产生的变链素对口腔链球菌的抑制活性,探讨变链素的产生与其致龋性及口腔微生态的关系.方法 从10例高龋儿童和10例无龋儿童牙菌斑内分离、鉴定得到80株变形链球菌临床分离株,分为高龋组和无龋组.用平板法检测两组菌株产生的变链素对口腔链球菌Streptococcus oralis ATCC 10557的抑制情况,观察两组菌株产生的抑菌环大小, 测量记录数据,T检验比较两组菌株抑菌环均数差异.结果 高龋组产生的抑菌环平均值为10.4 mm,无龋组平均值为6.9 mm,T检验显示差异具有显著性(t值为3.098,P<0.05).结论 高龋菌株产生的变链素对ATCC 10557有更大的抑制活性,变链素对口腔链球菌的抑制活性与其致龋力呈正相关.     

茵陈内生细菌的分离鉴定与抑菌活性成分分析

为从中药茵陈中分离内生细菌,筛选具有抑菌活性的菌株,分析活性成分。研究采用7种不同的培养基分离菌株,对分离到的菌株进行形态学和分子生物学鉴定,并对发酵产物进行抑菌活性测定,并利用分光光度法和高效液相色谱法分析抑菌活性较高的菌株发酵液活性成分。结果表明从茵陈新鲜组织中共分离到52株内生细菌,分属于9个种,芽孢杆菌为优势菌群。筛选得到具有抑菌活性的菌株17株,其中NA-3、BPA-24和KMB-32 3株菌活性较强,NA-3和KMB-32的发酵液中齐墩果酸含量较高。本研究通过分离纯化茵陈内生细菌,明确了茵陈内生细菌的菌群类别,获得了产齐墩果酸的两个菌株,为微生物发酵生产活性物质提供了素材。     

乳酸菌的分离、鉴定及其生长特性

从动物粪便中分离乳酸菌,得到产酸快、代谢物抑菌活性强的乳酸菌菌株共６株。其中Ｏ－２菌株的产酸、抑菌、耐酸、耐胆盐和生长性能都优于其他菌株,是一株有潜质的有益菌菌性,经鉴定表明为乳杆菌。不同的营养配比的液体培养基进行发酵实验表明,Ｒ２培养基配料简单,成本低,发酵２４ｈ产生的菌体总数多,４８ｈ培养液的抑菌活性强,且其抑菌活性具有一定的热稳定性。     

变链素活性与变形链球菌基因多态性的关系研究

目的探讨变链素的活性与变形链球菌(MS)基因多态性的关系。方法在AP-PCR基因分型的基础上,选择来自单基因型定植的个体50株MS为单基因型组,另50株来自多基因型共同定植的个体为多基因型组,用平板法检测2组菌株产生变链素对10个指示株的抑制情况,T-检验比较2组菌株抑菌环和抑菌谱的均数差异。结果所有的实验株(100%)均可产生抑制6~8个指示株的变链素,抑菌环和抑菌谱在不同个体之间变异,组间均数的比较不具有显著性(P值分别是0.12,1.79)。结论多基因型MS定植的口腔,在产生变链素方面似乎不具有优势。     

剑叶龙血树内生真菌的分离及体外抑菌活性筛选

为研究剑叶龙血树内生真菌资源多样性,初步探讨和筛选具有抑菌活性的特异性菌株以及进一步开发剑叶龙血树内生真菌的抗菌活性化合物。该文采用植物组织分离法从剑叶龙血树茎和叶中分离内生真菌,对内生真菌进行液体发酵7 d,经乙酸乙酯萃取后制得粗提物,并采用牛津杯扩散法,以10种常见病原菌和5种临床耐药菌为靶标检测其发酵粗提物的抑菌活性,对有较好抑菌活性的内生真菌进行分子鉴定。结果表明:(1)从剑叶龙血树茎、叶中共分离得到345株内生真菌,294株对一种以上指示菌有抑制活性;(2)其中84株内生真菌对5株临床耐药菌均有不同程度的抑制活性,占所分离菌株总数的24.35%,75%的内生真菌对金黄色葡萄球菌有抑制活性。这说明剑叶龙血树中存在多种有抑菌活性的内生真菌,为剑叶龙血树内生菌抗菌活性成分挖掘及新型抗菌药物筛选奠定了基础。     

解淀粉芽胞杆菌BaX030的分离鉴定及抗菌功能

摘要:【目的】芽胞杆菌是微生物活性物的重要来源,从全国各地采集的72份土壤样品中分离出339株芽胞杆菌,研究各菌株抑菌活性,分离纯化抑菌活性物,为丰富芽胞杆菌菌种资源和微生物次级代谢物的挖掘奠定实际应用基础。【方法】采用水浴加热和稀释平板涂布等方法从河南花生地采集的土壤中筛选得到一株具有很强抑菌活性的芽胞杆菌,结合形态观察、生理生化特征和16S rRNA基因序列同源性比对分析,对该菌株进行鉴定。丙酮沉淀、葡聚糖凝胶柱层析、C18反相柱层析得到Bacillus amyloliquefaciens X030抑菌活性物,LC-MS/MS鉴定其分子量。利用滤纸片扩散法和平板对峙培养法测定抑菌谱及拮抗性质。【结果】筛选分离得到一株解淀粉芽胞杆菌,归类并命名为解淀粉芽胞杆菌Bacillus amyloliquefaciens X030。BaX030对金黄色葡萄球菌(Staphylococcus aureus)、白色念珠菌(Candida albicans)、酵母菌( Saccharomycetes)有较强抑制效果,对水稻稻瘟病菌(Pyriculariaoryzae)、辣椒尖胞炭疽病菌(Chili pointed cell anthrax)、枇杷炭疽病菌(Gloeosporium eriobotryae speg)、烟草黑胫病菌(Phytophthora parasitica)有良好拮抗活性。初步确定BaX030产生的抑菌活性物为多肽类化合物。【结论】分离得到的B． amyloliquefaciens X030产生了一个对病原细菌具有较强抑制作用的多肽,同时该菌株在拮抗植物病原真菌方面也有明显的效果。     

一株蜂粮源拮抗细菌的分离鉴定及其抑菌物质特性

【目的】为发掘和利用蜂粮中拮抗菌资源,对分离获得的拮抗细菌菌株PC2进行分类鉴定,并测定其发酵液抑菌物质基本特性。【方法】采用改良牛津杯双层平板法测定菌株发酵液抑菌谱及温度、p H、紫外线和蛋白酶对其抑菌活性稳定性的影响,菌株鉴定结合形态学、生理生化特征和16S r RNA基因序列分析,硫酸铵沉淀法和盐酸沉淀有机溶剂提取法进行抑菌活性物质的初步分离。【结果】从3种蜂粮中分离筛选得到17株拮抗菌株,其中1株细菌PC2以马铃薯葡萄糖液体培养基发酵制备的无菌发酵液对7种供试菌株具有较强抑制作用,经形态、生理生化特征及16S r RNA基因序列分析,将其初步鉴定为解淀粉芽胞杆菌(Bacillus amyloliquefaciens)。菌株发酵液抑菌活性对温度、酸和紫外线具有较强的稳定性,对蛋白酶K、胃蛋白酶、碱性蛋白酶处理敏感。菌株发酵液存在抑菌蛋白和脂肽类物质。【结论】菌株PC2在食品保鲜和农业生防中具有潜在的开发应用价值。     

解淀粉芽孢杆菌BA-26抗菌物质分离及对灰葡萄孢抑菌作用研究

分析解淀粉芽孢杆菌(Bacillus amyloliquefaciens)BA-26发酵液中抑菌物质存在情况,明确活性物质的抑菌效果,初步探索其抗植物病原真菌的作用机制。通过硫酸铵沉淀、大孔树脂吸附及反相高效液相色谱法(RP-HPLC),从菌株BA-26的发酵液中分离纯化抗菌物质;采用平板对峙法检测抗菌物质抑菌活性;用二倍稀释法测定各活性组分的最小抑菌浓度(MIC),并研究其对菌丝和孢子萌发的影响。从菌株BA-26发酵液中获得抗菌粗提物抑菌谱广,对立枯丝核菌等多种植物病原真菌有强抑制作用;分离纯化得到11个具有抑制真菌作用的活性组分;其中A6-19和A6-20组分对灰葡萄孢(Botrytis cinerea)抑菌活性最强,最小抑菌浓度为7.81μg/mL;菌株BA-26产生的抗真菌活性物质能使灰葡萄孢菌丝生长受阻、膨大变粗、细胞膜破坏并能抑制其孢子萌发。明确了解淀粉芽孢杆菌BA-26菌株产抗菌物质情况,初步探究其抑菌作用机制,为抗菌物质在防治病原真菌等方面的应用奠定基础。     

西藏仲巴五彩沙漠放线菌资源勘探及生物活性筛选

【背景】细菌耐药性问题日益严峻,新抗生素的研发速度远远落后于临床需要,从特殊生境中挖掘微生物药物资源有望解决以上问题。【目的】勘探西藏仲巴五彩沙漠土壤放线菌多样性并进行生物活性筛选,为发现药用放线菌资源、开发新型抗生素奠定基础。【方法】采用8种分离培养基,通过平板稀释涂布法分离放线菌;根据分离菌株的16S r RNA基因序列同源性分析放线菌多样性;采用PCR技术对分离的放线菌菌株进行II型聚酮合酶(PKS-II)酮缩酶结构域KS、非核糖体多肽合成酶(NRPS)腺苷酸化结构域A、安莎类抗生素生物合成前体3-氨基-5-羟基-苯甲酸合酶(AHBA)保守区、黄素腺嘌呤二核苷酸卤化酶(Halo)保守区抗生素生物合成基因检测;对生物合成基因检测阳性的菌株进行液体发酵,发酵液经乙酸乙酯萃取、菌体经丙酮浸提,获得提取浓缩物样品进行抑菌活性和抗氧化活性筛选。【结果】从4份土样中分离纯化到231株放线菌,分布于7个属,其中链霉菌为优势菌属。68株放线菌的生物合成基因分析显示至少具有1种生物合成基因簇,其中6株同时具有4种生物合成基因簇;进一步的抑菌活性检测显示所有检测的菌株至少表现为对1株检定菌具有抑菌活性,其中8株具有广谱抗菌活性;抗氧化活性筛选结果为13株显示总抗氧化能力阳性,10株具有较好的羟自由基清除能力,3株显示较强的氧自由基清除能力。【结论】西藏仲巴五彩沙漠土壤中含有较丰富的放线菌药用资源,具有从中发现放线菌新菌种和开发新抗生素的潜力。     

解淀粉芽孢杆菌TF28抗菌脂肽芬芥素的分离鉴定及抑菌作用

对一株解淀粉芽孢杆菌TF28产生的抗菌脂肽进行分离鉴定及抑菌活性研究,采用酸沉淀、乙酸乙酯和甲醇萃取技术制备了抗菌脂肽粗提物,经过2次HPLC分离纯化,在保留时间32～42min内获得8个抗菌脂肽纯品,经MALDI-TOF-MS鉴定为芬芥素(fengycins),对尖孢镰刀菌和禾谷镰刀菌显示出较强的抑菌活性,该研究为提高菌株TF28抗菌脂肽产量的定向遗传改造奠定基础。     

Streptococcus mutans strain N produces a novel low molecular mass non-lantibiotic bacteriocin

Streptococcus mutans strain N was shown to have bacteriocin production and immunity characteristics consistent with those of Group I mutacin-producing strains of S. mutans. The bacteriocin mutacin N was purified from agar cultures of S. mutans strain N using XAD andp6 reversed phase chromatography. The molecular mass of mutacin N was 4806 Da and the entire 49 amino acid sequence was determined by N-terminal sequencing. Database searches indicate that mutacin N is a novel bacteriocin, but with some homology to the protein IIC domain of a hypothetical sugar-phosphotransferase enzyme from Acholeplasma florum.     

Purification and properties of extracellular mutacin, a bacteriocin from Streptococcus sobrinus.

Mutacin MT6223, a cell-free bacteriocin produced by Streptococcus sobrinus MT6223, was purified by ammonium sulphate precipitation, chromatofocusing with PBE 94 and column chromatography on SP Sephadex C-25. The specific activity of the purified mutacin was increased 1950-fold with a recovery of 9.7%. The molecular mass of the purified mutacin preparation was estimated to be 6.5 kDa. The mutacin activity was stable from pH 2-7, and was resistant to treatment at 100 degrees C for 20 min. It was inactivated by papain or ficin digestion, and was partially inhibited by alpha-chymotrypsin. The mutacin was found to be active against strains of serotypes c, e and f of Streptococcus mutans and the addition of purified mutacin MT6223 to growing cells of S. mutans MT8148 resulted in a rapid inhibition of incorporation of [3H]thymidine, [3H]uracil or L-[3H]glutamic acid into DNA, RNA or protein, respectively. Specific pathogen-free Fischer rats fed diet 2000 and infected with S. mutans MT8148R showed significantly fewer caries and lower plaque scores when mutacin was administered through drinking water. The present study demonstrates that mutacin MT6223 inhibited the growth of mutans streptococci. Thus, mutacin MT6223 may be a candidate for use in dental caries prevention.     

Population structure of plasmid-containing strains of Streptococcus mutans, a member of the human indigenous biota

There are suggestions that the phylogeny of Streptococcus mutans, a member of the human indigenous biota that is transmitted mostly mother to child, might parallel the evolutionary history of its human host. The relatedness and phylogeny of plasmid-containing strains of S. mutans were examined based on chromosomal DNA fingerprints (CDF), a hypervariable region (HVR) of a 5.6-kb plasmid, the rRNA gene intergenic spacer region (IGSR), serotypes, and the genotypes of mutacin I and II. Plasmid-containing strains were studied because their genetic diversity was twice as great as that of plasmid-free strains. The CDF of S. mutans from unrelated human hosts were unique, except those from Caucasians, which were essentially identical. The evolutionary history of the IGSR, with or without the serotype and mutacin characters, clearly delineated an Asian clade. Also, a continuous association with mutacin II could be reconstructed through an evolutionary lineage with the IGSR, but not for serotype e. DNA sequences from the HVR of the plasmid produced a well-resolved phylogeny that differed from the chromosomal phylogeny, indicating that the horizontal transfer of the plasmid may have occurred multiple times. The plasmid phylogeny was more congruent with serotype e than with mutacin II evolution, suggesting a possible functional correlation. Thus, the history of this three-tiered relationship between human, bacterium, and plasmid supported both coevolution and independent evolution.     

The specific genes for lantibiotic mutacin II biosynthesis in Streptococcus mutans T8 are clustered and can be transferred en bloc

Mutacin II is a ribosomally synthesized peptide lantibiotic produced by group II Streptococcus mutans. DNA sequencing has revealed that the mutacin II biosynthetic gene cluster consists of seven specific open reading frames: a regulator (mutR), the prepromutacin structural gene (mutA), a modifying protein (mutM), an ABC transporter (mutT), and an immunity cluster (mutFEG). Transformations of a non-mutacin-producing strain, S. mutans UA159, and a mutacin I-producing strain, S. mutans UA140, with chromosomal DNA from S. mutans T8 with an aphIII marker inserted upstream of the mutacin II structural gene yielded transformants producing mutacin II and mutacins I and II, respectively.     

Effects of dietary carbohydrates on mutacin production and activity

Although mutacins (bacteriocins produced by Streptococcus mutans) were shown to be active in vivo, their ecological role in the oral cavity is still controversial. In the present paper, the effect of dietary carbohydrates, one of the ecological parameters which influences oral bacterial populations, on the activity and the production of mutacins from four S. mutans strains (C67-1, Ny257, Ny266 and T8) is described. Results obtained by the deferred antagonism test in solid media and by the mixed cultivation of the mutacinogenic strains with a sensitive indicator strain in liquid batch cultures, indicate that a minimal fermentable sugar concentration is needed for mutacin production. Among all the fermentable carbohydrates tested (fructose, glucose, lactose, mannitol and sucrose), none significantly affected the production and the activity of the four mutacinogenic strains used, in concentrations up to 5%. Although the results do not discount the possibility of mutacin inactivation in vivo, they indicate that they are not affected by dietary carbohydrates.     

Properties of mutacin b, an antibacterial substance produced by Streptococcus mutans strain BHT

An antibacterial substance produced by strain BHT of Streptococcus mutans (mutacin b) was found to be a small molecule (MW 3,500-6,000) with remarkable resistance to temperature, alkali and various solvents. Enzyme sensitivity tests of partially purified preparations indicated that mutacin b is a peptide. It is sensitive to several proteolytic enzymes and its lethal effects on sensitive cells can be prevented by adding trypsin to cells exposed to mutacin b. High concentrations of mutacin b inhibited the growth of producer cells, indicating that strain BHT is only partially immune to this substance.     

Co-ordinated bacteriocin production and competence development: a possible mechanism for taking up DNA from neighbouring species

It is important to ensure DNA availability when bacterial cells develop competence. Previous studies in Streptococcus pneumoniae demonstrated that the competence-stimulating peptide (CSP) induced autolysin production and cell lysis of its own non-competent cells, suggesting a possible active mechanism to secure a homologous DNA pool for uptake and recombination. In this study, we found that in Streptococcus mutans CSP induced co-ordinated expression of competence and mutacin production genes. This mutacin (mutacin IV) is a non-lantibiotic bacteriocin which kills closely related Streptococcal species such as S. gordonii. In mixed cultures of S. mutans and S. gordonii harbouring a shuttle plasmid, plasmid DNA transfer from S. gordonii to S. mutans was observed in a CSP and mutacin IV-dependent manner. Further analysis demonstrated an increased DNA release from S. gordonii upon addition of the partially purified mutacin IV extract. On the basis of these findings, we propose that Streptococcus mutans, which resides in a multispecies oral biofilm, may utilize the competence-induced bacteriocin production to acquire transforming DNA from other species living in the same ecological niche. This hypothesis is also consistent with a well-known phenomenon that a large genomic diversity exists among different S. mutans strains. This diversity may have resulted from extensive horizontal gene transfer.     

Identification of nlmTE, the locus encoding the ABC transport system required for export of nonlantibiotic mutacins in Streptococcus mutans

Streptococcus mutans UA159, the genome sequence reference strain, exhibits nonlantibiotic bacteriocin (mutacin) activity. In this study, we have combined bioinformatic and mutational analyses to identify the ABC transporter designated NlmTE, which is required for mutacin biogenesis in strain UA159 as well as in another mutacin producer, S. mutans N.     

The group I strain of Streptococcus mutans, UA140, produces both the lantibiotic mutacin I and a nonlantibiotic bacteriocin, mutacin IV

Strains of Streptococcus mutans produce at least three mutacins, I, II, and III. Mutacin II is a member of subgroup AII in the lantibiotic family of bacteriocins, and mutacins I and III belong to subgroup AI in the lantibiotic family. In this report, we characterize two mutacins produced by UA140, a group I strain of S. mutans. One is identical to the lantibiotic mutacin I produced by strain CH43 (F. Qi et al., Appl. Environ. Microbiol. 66:3221-3229, 2000); the other is a nonlantibiotic bacteriocin, which we named mutacin IV. Mutacin IV belongs to the two-peptide, nonlantibiotic family of bacteriocins produced by gram-positive bacteria. Peptide A, encoded by gene nlmA, is 44 amino acids (aa) in size and has a molecular mass of 4,169 Da; peptide B, encoded by nlmB, is 49 aa in size and has a molecular mass of 4,826 Da. Both peptides derive from prepeptides with glycines at positions -2 and -1 relative to the processing site. Production of mutacins I and IV by UA140 appears to be regulated by different mechanisms under different physiological conditions. The significance of producing two mutacins by one strain under different conditions and the implication of this property in terms of the ecology of S. mutans in the oral cavity are discussed.